Thermo Fisher Scientific’s state-of-the-art sterile drug development and manufacturing facility in Singapore supports rapid fill finish vaccines and other therapeutics for an expanding biopharma market.
With support from the Singapore Economic Development Board, (EDB) this facility is an essential part of Thermo Fisher Scientific’s global network – now comprising of six facilities supporting aseptic manufacturing and sterile fill finish.
Our commitment to meeting scientists’ needs globally is further strengthened by this facility, which is designed to enhance our network for biomedical research, development, and commercialization.
To find out more about our unique site offerings, download our fact sheet below.
Existing Capabilities
Biopharmaceuticals
Expansion capabilities (not currently available)
| Size / details | Early Development (into part of phase ll) | Late development | Commercial supply | |||||
|---|---|---|---|---|---|---|---|---|
| Liquid vials | ||||||||
| Lyophilized vials (Expansion) | ||||||||
| Prefilled syringes (Expansion) | ||||||||
| Prefilled cartridges (Expansion) | ||||||||
⬤ Available now
✱ Future capabilities
To learn more about this site or to request a site tour, please contact us below.
The Thermo Fisher Scientific site in Brisbane, Australia is a state of the art facility, specializing in clinical and commercial manufacturing, and single use biologics technology. The Brisbane facility won the ISPE “2014 Facility of the Year” for Process Innovation, and is part of our global network of Biologics sites, which also includes St. Louis Missouri and Groningen, Netherlands.
Singapore is a hub to the Asia Pacific region due to its strategic location at the crossroads of international trade and shipping routes and its free trade policy.
Our highly experienced local Singapore team is supported by our network of Asia Pacific facilities, including Beijing & Suzhou in China, Japan, India and Korea, providing access to a global network with a local presence.